Hospital das Clínicas de Ribeirão Preto
12
4
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
8.3%
1 terminated/withdrawn out of 12 trials
66.7%
-19.8% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies
Role: collaborator
Inorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies
Role: collaborator
Melphalan Chemoreduction for Ocular Melanoma
Role: lead
Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Role: lead
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke
Role: lead
CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
Role: collaborator
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Role: lead
Lymphatic Morphology of Fontan Patients
Role: collaborator
Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window
Role: collaborator
Aesculus Hippocastanum L. on Fontan Circulation
Role: collaborator
Lymphatic Function in Patients With a Fontan Circulation From Brazil
Role: collaborator
Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk.
Role: collaborator
All 12 trials loaded